Biography
Doug Coyle has been a faculty member within the School since 1995, retiring in September 2024. Doug acted as Interim Director of the School from 2016-18 and was previously director of the graduate program in epidemiology.
Previously he worked at the Ottawa Health Research Institute and the Centre for Health Economics at the University of York. He is a health economist and obtained his PhD from Brunel University. His research focuses on improving the overall health of the population through the appropriate allocation of health care resources. He was one of the primary authors of the recent Canadian guidelines for economic evaluation. He has recently developed further guidance with respect to the extrapolation of clinical data and model validation. Doug has published extensively in this area (>300 peer reviewed articles) and has advised CADTH, Health Canada, the Public Health Agency of Canada and various provincial ministries of health with respect to methodology of economic evaluation and in reimbursement decisions relating to health care interventions. He has served as a member of the Canadian Expert Drug Advisory Committee, Ontario Ministry of Health and Long Term Care's Committee to Evaluate Drugs and Drugs for Rare Diseases Working Group and the Health Economics Advisory Group for CADTH.
Doug developed two graduate courses within SEPH (Health Economic Evaluation and Advanced Health Economic Evaluation). He has supervised and co-supervised over 40 MSc and PhD students over his career. Doug was awarded the Career Achievement Award by the Society of Medical Decision Making in 2021 and the Dr Jill M Sanders Award of Excellence in Health Technology Assessment by Canada’s Drug Agency in 2024.
Selected Publications (since 2020)
Coyle D. Implementing a "Smoke Free Generation" policy for Canada: estimates of the long term impacts. Health Promotion and Chronic Disease Prevention in Canada. 2025;45 (1):39-53.
Coyle D. Considerations when applying equity weights within economic evaluation when making drug reimbursement decisions. Health Econ Rev. 2024 Nov 13;14(90):1-7.
Motazedian P, Prosperi-Porta G, Hibbert B, Jalal H, Labinaz M, Burwash IG, Abdel-Razek O, Santo PD, Simard T, Wells G, Coyle D. Cost-effectiveness of population screening for aortic stenosis. Eur Heart J Qual Care Clin Outcomes. 2024 May. Epub ahead of print.
Agarwal A, Kekre N, Atkins H, Imsirovic H, Hutton B, Coyle D, Thavorn K. Phase-based and lifetime health system costs of care for patients diagnosed with leukemia and lymphoma: a population-based descriptive study. Current Oncology 2024 Jul 25;31(8):4192-4208.
Coyle D, Haines A, Lee K. The development of a model validation tool to assist in the conduct of economic evaluations. Canadian Journal of Health Technologies. 2024:4:3.
Boczar KE, Beanlands R, Wells G, Coyle D. Cost-effectiveness of colchicine for recurrent cardiovascular events. CJC Open. 2023:5:348-356.
Khan F, Coyle D, Thavorn K, van Katwyk S, Tritschler T, Hutton B, et al. Indefinite anticoagulant therapy for first unprovoked venous thromboembolism a cost-effectiveness study Annals of InternalMedicine. 2023 Jul;176(7):949-960.
Leahy T, Durand-Zaleski I, Sampietro-Colom L, Zöllner Y, Coyle D, Casadei G. The role of quantitative bias analysis for non-randomised comparisons in health technology assessment: Recommendations from an expert workshop. International Journal of Technology Assessment in Health Care 2023; 39: e68.
Coyle D, Haines A, Lee K. Extrapolating clinical evidence within economic evaluations. Canadian Journal of Health Technologies. 2023:3:5.
Rowlands Snyder EC, McGregor E, Coyle D. Universal ophthalmia neonatorum prophylaxis in Canada: a cost-effectiveness analysis. CMAJ Open. 2023 Jan 17;11(1):E33-E39.
Boczar KE, Beanlands R, Wells G, Coyle D. Cost-effectiveness of canakinumab from a Canadian perspective for recurrent cardiovascular events. CJC Open. 2022 Jan 17;4(5):441-448.
Krewski D, Saunders-Hastings P, Larkin P, Westphal M, Tyshenko MG, Leiss W, Dusseault M, Jerrett M, Coyle D. Principles of risk decision-making. J Toxicol Environ Health. 2022 Jul 4;25(5):250-278
Scarffe AD, Licskai CJ, Ferrone M, Brand K, Thavorn K, Coyle D. Cost-effectiveness of integrated disease management for high risk, exacerbation prone, patients with chronic obstructive pulmonary disease in a primary care setting. Cost Eff Resour Alloc. 2022 Aug 12;20(1):39.
Pound C, Coyle D. A cost-utility analysis of the impact of electronic nicotine delivery systems on health care costs and outcomes in Canada. Health Promot Chronic Dis Prev Can. 2022 Jan;42(1):29-36.
Gaskin J, Whyte J, Zhou G, Coyle D. Regional cost effectiveness analyses for increasing radon. protection strategies in housing in Canada. 2021: 240; 106752.
Elliott J, Wells GA, Coyle D. The Continued Need for Transparent Evidence on the Cost Effectiveness of Drugs for Rare Diseases. Pharmacoeconomics. 2021 Apr;39(4):479-480.
Coyle K, Quan AML, Wilson LA, Hawken S, Bota AB, Coyle D, Murray JC, Wilson K. Cost-effectiveness of a gestational age metabolic algorithm for preterm and small-for-gestational-age classification. Am J Obstet Gynecol MFM. 2021 Jan;3(1):100279.
Bennett A, Thavorn K, Arendas K, Coyle D, Singh SS. Outpatient uterine assessment and treatment unit in patients with abnormal uterine bleeding: an economic modelling study. CMAJ Open. 2020 Dec 8;8(4):E810-E818.
Abu-Raya B, Coyle D, Bettinger JA, Vaudry W, Halperin SA, Sadarangani M; for members of the Canadian Immunization Monitoring Program, ACTive (IMPACT). Pertussis vaccination in pregnancy in Canada: a cost-utility analysis. CMAJ Open. 2020 Oct 19;8(4):E651-E658.
Coyle D, Durand-Zaleski I, Farrington J, Garrison L, Graf von der Schulenburg JM, Greiner W et al. HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. Eur J Health Econ. 2020 Dec;21(9):1421-1437.
Coyle D. Who would benefit from average value-based pricing? Health Econ. 2020 Aug;29(8):936-937.
Elliott J, McCoy B, Clifford T, Potter BK, Wells GA, Coyle D. Economic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility Analysis. Pharmacoeconomics. 2020 Sep;38(9):971-980.
Gaskin J, Whyte J, Coyle D. An assessment of uncertainty using two different modelling techniques to estimate the cost effectiveness of mitigating radon in existing housing in Canada. Sci Total Environ. 2020 Jul 1;724:138092.
Coyle D, Villeneuve PJ. Economic evaluation of azacitidine in elderly patients with acute myeloid leukemia with high blast counts. Pharmacoecon Open. 2020;4:297–305